RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine

Background Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. Methods RBD-specific antibody titres, as a rapidly available and highly predictive surrogat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC infectious diseases Jg. 22; H. 1; S. 87 - 11
Hauptverfasser:	Ferenci, Tamás, Sarkadi, Balázs
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 24.01.2022 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Accreditation Age Aged Antibodies Antibody Formation Antibody response BBIBP-CorV Beijing Coronaviruses COVID-19 COVID-19 vaccines Disease Humans Infections Infectious Diseases Internal Medicine Laboratories Medical Microbiology Medicine Medicine & Public Health Older people Parasitology SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Sex Statistical analysis Testing Tropical Medicine Vaccination Vaccine Vaccines Viral antibodies Viral diseases Beijing Hungary Beijing China China COVID-19 SARS-CoV-2 Vaccine BBIBP-CorV Antibody response
ISSN:	1471-2334, 1471-2334
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!